Pinnacle Wealth Planning Services
CRSP icon

Pinnacle Wealth Planning Services’s CRISPR Therapeutics CRSP Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.13K Buy
165
+47
+40% +$2.54K ﹤0.01% 2114
2026
Q2 		$6.44K Sell
118
-42
-26% -$2.21K ﹤0.01% 2230
2026
Q1 		$7.61K Sell
160
-1
-0.6% -$53 ﹤0.01% 2117
2025
Q4 		$8.44K Buy
+161
New +$9.6K ﹤0.01% 2077

Other funds holding CRSP

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pinnacle Wealth Planning Services's CRSP Position: Q3 2026 in Review

Pinnacle Wealth Planning Services increased its CRISPR Therapeutics (CRSP) stake by 40% in Q3 2026, buying an estimated $2.54K and bringing the position to 165 shares worth $9.13K. The position accounts for ﹤0.01% of the portfolio, ranked #2114.

Pinnacle Wealth Planning Services first reported a position in CRSP in Q4 2025 and has held it in 4 quarters since. 340 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Pinnacle Wealth Planning Services held 165 shares of CRISPR Therapeutics worth $9.13K as of Q3 2026.
  • Pinnacle Wealth Planning Services bought 47 CRISPR Therapeutics shares in Q3 2026, an estimated $2.54K.
  • CRISPR Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q3 2026, its #2114 holding.
  • Pinnacle Wealth Planning Services first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 340 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q3 2026, filed 27 Oct 2026.